The Medical Advisor

In the ever-evolving field of oncology, understanding genetics and genomics is crucial for patients, families, and healthcare providers alike. Genetics focuses on the study of genes and their role in inheritance—how certain traits or conditions are passed from one generation to the next. Genetic testing identifies inherited mutations present in every cell of the body since birth (known as germline testing). This can be performed via a blood test, cheek swab, or saliva sample. In cancer care, it's vital because it detects inherited predispositions to specific cancers, such as those linked to BRCA1/2, ATM, PALB2, CHEK2, BRIP1, Lynch syndrome, and others. These insights inform treatment choices, surveillance strategies, risk-reduction measures, and family testing recommendations. Genomics, on the other hand, examines a person's entire genome. In cancer, genomic testing analyzes the tumor cells to pinpoint gene or protein alterations that distinguish them from healthy cells. By seq...

Nicolas Hulscher and colleagues conducted a survey of 197 Cancer patients taking Ivermectin and Mebendazole for 6 months (abstract below) and confirmed: 84.4% reported a clinical benefit  32.8% reported No evidence of disease  15.6% reported tumor regression The study began with 197 cancer patients, and 122 completed follow-up. Patients were prescribed capsules containing 25 mg ivermectin and 250 mg mebendazole. They took up to 4 capsules per day according to physician’s recommendation.   Dr William Makis posted on X.com (April 2026): This confirms what we've seen in the 9000+ Cancer patients we helped in our largest Ivermectin Cancer Project in the world! I've often talked about a 75-80% clinical benefit that patients reported when they came to us, with some cancer patients getting tumor shrinkage, some getting stabilization of disease and some succeeding in preventing recurrence! Self-reported cancer outcomes at 6-month follow-up (N=122) Real-World Clinical Outcome...